GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » Beta

Remus Pharmaceuticals (NSE:REMUS) Beta : N/A (As of Dec. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Remus Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-11), Remus Pharmaceuticals's Beta is Not available.


Remus Pharmaceuticals Beta Historical Data

The historical data trend for Remus Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remus Pharmaceuticals Beta Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar24
Beta
- - - -

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep23 Mar24 Sep24
Beta Get a 7-Day Free Trial - - - - -

Competitive Comparison of Remus Pharmaceuticals's Beta

For the Medical Distribution subindustry, Remus Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remus Pharmaceuticals's Beta Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's Beta falls into.



Remus Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Remus Pharmaceuticals  (NSE:REMUS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Remus Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Remus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.

Remus Pharmaceuticals Headlines

No Headlines